SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Trimel Announces Voting Results for 2014 Annual General and Special Shareholders' Meeting

TORONTO, ONTARIO -- (Marketwired) -- 06/12/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the voting results from its annual general and special meeting held on June 12, 2014. The total number of shares represented in person or by proxy at the meeting was 121,019,361, representing 74.19% of Trimel's total issued and outstanding shares.

Shareholders voted in favour of the reappointment of the auditors of the company, in favour of ratifying the amended and restated by-laws of the company and voted as follows in connection with the election of the directors of the company:



----------------------------------------------------------------------------
Name                                  Votes For (%)       Votes Withheld (%)
----------------------------------------------------------------------------
Ian Ihnatowycz                  83,341,992 (69.43%)      36,695,676 (30.57%)
----------------------------------------------------------------------------
John Friedrichsen              120,019,043 (99.99%)           18,625 (0.01%)
----------------------------------------------------------------------------
Stephen Gregory                119,926,872 (99.91%)          110,796 (0.09%)
----------------------------------------------------------------------------
Matthew Pfeffer                 83,323,600 (69.41%)      36,714,068 (30.59%)
----------------------------------------------------------------------------
Rolf Reininghaus               119,358,688 (99.43%)          678,980 (0.57%)
----------------------------------------------------------------------------
Tom Rossi                       79,224,277 (66.00%)      40,813,391 (34.00%)
----------------------------------------------------------------------------
Jeffrey Sherman                 78,541,818 (67.69%)      37,495,850 (32.31%)
----------------------------------------------------------------------------
Dr. D. Lorne Tyrrell           120,006,599 (99.98%)           31,069 (0.02%)
----------------------------------------------------------------------------

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at [email protected].

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.